NCT04439214View on ClinicalTrials.gov

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 11, 2018

Study Completion Date

May 17, 2020

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04439214 - Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | Biotech Hunter | Biotech Hunter